



# Placebo Analgesia Correlates with High-Frequency Heart Rate Variability

Karl A. Neumann<sup>1</sup>, Elizabeth A. Necka<sup>1</sup>, Danny McDermott<sup>1,3</sup>, Esther Palacios-Barrrios<sup>2</sup>, Lauren Y. Atlas<sup>1,4</sup>

<sup>1</sup> National Center for Complementary & Integrative Health, NIH,

<sup>2</sup> University of Pittsburgh, <sup>3</sup> University of Arizona, <sup>4</sup> National Institute of Drug Abuse, NIH



## Introduction

- Increased high-frequency heart rate variability (i.e. respiratory sinus arrhythmia) is a proxy of parasympathetic activity and associated with positive health outcomes<sup>1</sup>.
- Placebo analgesia (i.e. pain relief) is associated with changes in autonomic activity<sup>4</sup>. The parasympathetic nervous system is a possible contributor to placebo analgesia due to its internal regulatory properties<sup>3</sup>.
- Individual differences in emotion regulation and autonomic flexibility are hypothesized to be associated with greater placebo responses<sup>2,3,5</sup>.
- In this exploratory study, we manipulated subjects' analgesic expectations of inert skin creams and administered pain to isolate and quantify placebo responses.

## Methods & Materials


**Participants:** N = 17 Participants, aged 19-42 (M=26.35, SD = 6.26), 11 female

**Conditions:** Cream/Expectation (None, Control, Placebo), Heat (Low Heat, Med Heat, High Heat)

### Procedure/Task Design:

#### Initial Heat, No Creams (Pre)

- Patient received low, medium, and high heat on their left forearm
- Rated pain on VAS 10-point scale
- ECG measured throughout study



#### Conditioning

Expectation: Reality:

Control	Level 7	Level 7
Placebo	Level 7	Level 3

"To test if it's working, we'll administer your level 7"

ECG measured throughout experiment

#### Placebo & Control Blocks (Counterbalanced)

- Patients receive 2 blocks with stimulus expectancy cues and 2 without.
- 4 blocks per condition
- 8 trials per block

**Measures:** Respiratory Sinus Arrhythmia or RSA (the variability in ECG due to breathing) using Mindware™ HRV analysis toolbox, Subjective Pain reported using 10-point Visual Analogue Scale (VAS)





Diagram of the spectral analysis used to derive RSA from ECG signals taken from .12hz to .4hz



Visual Analogue Scale (VAS) used by participants to communicate their acute pain



Distance between peaks of each QRS complex and the variability of those distances correspond with RSA.

**Statistical Methods:** One-way repeated measures ANOVA, correlations, and a mixed effects model.

## Results & Figures

### Descriptive Statistics & Correlations for RSA

Measure	Mean	St. Deviation
RSA Pre	6.72	1.066
RSA Placebo	6.79	1.195
RSA Control	6.78	1.199

Correlation Table		
Measure	RSA Pre	RSA Placebo
RSA Pre		
RSA Placebo	.902**	
RSA Control	.935**	.960**

\* = P<.05, \*\* = P<.001

### One-Way Repeated Measures ANOVA of RSA by Expectation of Treatment (Pre, Placebo, Control):

Effect	Expectation of Treatment	Mean	Std. Deviation	df	Sphericity Assumed	df	Greenhouse-Geisser	F	Sig.	Sphericity Assumed	Sig.	Greenhouse-Geisser
RSA	Pre	6.727	1.086	2		1.648		.186	.871			.790
	Placebo	6.790	1.195	2		1.648		.186	.871			.790
	Control	6.768	1.199	2		1.648		.186	.871			.790

Results non-significant, p-value = .831 if sphericity is assumed, p = .790 using Greenhouse-Geisser


### Descriptive Statistics & Correlations for Placebo Responses

Measure	Mean	St. Deviation
Low Heat (Control - Placebo)	.122	.556
Medium Heat (Control - Placebo)	.612	.948
High Heat (Control - Placebo)	.155	.998

Correlation Table			
Measure	RSA Pre	RSA Placebo	RSA Control
Low Heat (Control - Placebo)	.120	.258	.109
Medium Heat (Control - Placebo)	.542*	.588*	.483*
High Heat (Control - Placebo)	-.006	.113	.094

\* = P<.05, \*\* = P<.001

### Mixed Effects Model of RSA & Pain:



Results were significant with  $B = .30(.12)$ ,  $t(93.15) = 2.40$ ,  $p = .018$ .  $N = 17$

## Conclusions

- Novel evidence demonstrates the correlation between placebo analgesia and individual RSA, such that higher RSA correlates with a greater placebo response.
- Contrary to the literature, we found RSA did not change significantly between conditions (Pre, Control, Placebo).
- These results provide further evidence for an autonomic aspect of the placebo response, specifically parasympathetic activity.
- It is unclear whether RSA and the parasympathetic nervous activity it represents is directly affecting pain scores or whether it is only symptomatic of the reduction of pain scores that drive the change.
- Provides a biological basis for further investigation into the psychological mediators of increased RSA, such as emotion regulation, and their role in placebo analgesia.
- Raises the possibility for future studies to determine the direction of causality between RSA & placebo analgesia and other mediating variables driving the correlation.

## References

- Berntson, Gary G., et al. "Respiratory Sinus Arrhythmia: Autonomic Origins, Physiological Mechanisms, and Psychophysiological Implications." *Psychophysiology*, vol. 30, no. 2, 1993
- Hampton, Amy J. D., et al. "The Effects of Emotion Regulation Strategies on the Pain Experience." *Pain*, vol. 156, no. 5, 2015, pp. 868-879.
- Meissner, K. "The Placebo Effect and the Autonomic Nervous System: Evidence for an Intimate Relationship." *Philosophical Transactions of the Royal Society B: Biological Sciences*, vol. 366, no. 1572, 2011
- Nakamura, Yoshio, et al. "Investigating Dose-Dependent Effects of Placebo Analgesia: A Psychophysiological Approach." *Pain*, vol. 153, no. 1, 2012, pp. 227-23
- Wager, Tor D., and Lauren Y. Atlas. "The Neuroscience of Placebo Effects: Connecting Context, Learning and Health." *Nature Reviews Neuroscience*, vol. 16, no. 7, 2015, pp. 403-418

## Acknowledgements

This project would not have been possible without the help of the entire ANP Lab, and specifically the mentorship of Dr. Elizabeth Necka and Dr. Lauren Atlas. Thanks to the medical and nursing staff of OP4 that contributed to this project, such as Bisi Ayodele, NP, Linda Ellison-Dejewski, NP, and Danny Pine, MD. Further thanks to Troy Dildine for writing the script that helped with my analyses.